Spero Therapeutics
SPRO
61 hedge funds and large institutions have $122M invested in Spero Therapeutics in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 10 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
160% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 10
11% more funds holding
Funds holding: 55 → 61 (+6)
6.94% more ownership
Funds ownership: 53.81% → 60.74% (+6.9%)
3% more capital invested
Capital invested by funds: $119M → $122M (+$3.78M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$5.77M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$5.61M |
| 3 |
BlackRock
New York
|
+$2.84M |
| 4 |
Renaissance Technologies
New York
|
+$1.22M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.93M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$856K |
| 3 |
AG
Artal Group
Luxembourg
|
-$722K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$490K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$202K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $8K | +$8.64K | +718 | New |
|
|
PCP
52
Proficio Capital Partners
Newton,
Massachusetts
| $7K | – | – | – |
|
|
RE
53
RBC Europe
London,
United Kingdom
| $6.88K | +$1.84K | +153 | +34% |
|
54
Twin Tree Management
Dallas,
Texas
| $6K | -$698 | -58 | -10% |
|
|
AIP
55
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | – | – | – |
|
|
PCM
56
Prelude Capital Management
New York
| $6K | +$6.02K | +500 | New |
|
|
EWM
57
Executive Wealth Management
Brighton,
Michigan
| $5K | – | – | – |
|
58
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
|
PAM
59
Panagora Asset Management
Boston,
Massachusetts
| $2K | +$1.96K | +163 | New |
|
60
Group One Trading
Chicago,
Illinois
| $1K | – | – | – |
|
|
61
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$490K | -38,222 | Closed |
|
62
Squarepoint
New York
| – | -$166K | -12,951 | Closed |
|
|
VF
63
Virtu Financial
New York
| – | -$134K | -10,465 | Closed |
|
|
AG
64
Advisor Group
Phoenix,
Arizona
| – | +$60 | +5 | New |
|
SPRO Hedge Fund Activity: Q2 2019 in Review
61 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2019, worth a combined $122M — up 3.2% from $119M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SPRO positions and 3 closed out — a net gain of 6 holders — while 26 added to existing stakes and 10 trimmed.
The largest buyer was BVF Inc, adding an estimated $5.77M. The largest seller was Fidelity Investments, cutting an estimated $1.93M.
- 61 institutional investors held Spero Therapeutics (SPRO) as of Q2 2019, up from 55 in Q1 2019.
- Funds reported $122M of Spero Therapeutics stock for Q2 2019, up 3.2% quarter-over-quarter.
- 9 funds opened new Spero Therapeutics positions in Q2 2019 and 3 closed out, a net change of +6 holders.
- The largest Spero Therapeutics buyer in Q2 2019 was BVF Inc, an estimated $5.77M added.
- The largest Spero Therapeutics seller in Q2 2019 was Fidelity Investments, an estimated $1.93M sold.
Based on aggregated 13F filings for Q2 2019.